Skip to main content

Advertisement

SpringerLink
Log in

Incidence and Risk Factors for Lymphoma in a Single-Center Inflammatory Bowel Disease Population

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Aims

Previous studies on the risk of lymphoma in inflammatory bowel disease (IBD) have yielded conflicting results. We aim to determine the incidence and risk factors for lymphoma in a large IBD population.

Methods

Patients with lymphoma were identified from a single-center IBD database. The standardized incidence ratio (SIR) of lymphoma was estimated using data from the Surveillance, Epidemiology and End Results (SEER) registry. Risk factors for lymphoma were determined by comparing cases with a matched IBD control group.

Results

Eleven lymphomas were identified among 3,585 IBD patients during an average of 8.4 years of observation. Three patients were excluded. In the remaining eight, median age at diagnosis was 47 years and mean IBD duration was 20 years (range 7.5–45 years). The SIR for lymphoma was 1.6 [95% confidence interval (CI) 0.6-3.0], and for non-Hodgkin lymphoma (NHL), 1.5 (0.3-2.8). Three lymphoma patients (38%) received prior immunomodulators and two (25%) received biologics, versus 57% and 39% in the control group, respectively (P = 0.4). No correlation was seen with tobacco exposure, disease duration, use, or dose or duration of immunosuppressive therapy.

Conclusions

In this IBD cohort, risk of lymphoma was not increased compared with the general population. Risk of lymphoma was not associated with any demographic or therapy-related factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

IBD:

Inflammatory bowel disease

NHL:

Non-Hodgkin lymphoma

HL:

Hodgkin lymphoma

IM:

Immunomodulators

TNF-α:

Tumor necrosis factor-α

References

  1. Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005;21:44–50.

    PubMed  Google Scholar 

  2. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–869.

    PubMed  CAS  Google Scholar 

  3. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–266.

    PubMed  CAS  Google Scholar 

  4. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut. 1995;37:674–678.

    Article  PubMed  CAS  Google Scholar 

  5. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.

    Article  PubMed  CAS  Google Scholar 

  6. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478–2485.

    Article  PubMed  CAS  Google Scholar 

  7. Korelitz BI, Sommers SC. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. Am J Gastroenterol. 1975;64:365–370.

    PubMed  CAS  Google Scholar 

  8. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429.

    Article  PubMed  CAS  Google Scholar 

  9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.

    Article  PubMed  CAS  Google Scholar 

  10. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.

    Article  PubMed  CAS  Google Scholar 

  11. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–250.

    Article  PubMed  CAS  Google Scholar 

  12. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–1811.

    Article  PubMed  Google Scholar 

  13. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.

    Article  PubMed  CAS  Google Scholar 

  14. D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–667.

    Article  PubMed  Google Scholar 

  15. Palli D, Trallori G, Bagnoli S, et al. Hodgkin’s disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000;119:647–653.

    Article  PubMed  CAS  Google Scholar 

  16. Arseneau KO, Stukenborg GJ, Connors AF Jr, Cominelli F. The incidence of lymphoid and myeloid malignancies among hospitalized Crohn’s disease patients. Inflamm Bowel Dis. 2001;7:106–112.

    Article  PubMed  CAS  Google Scholar 

  17. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854–862.

    Article  PubMed  CAS  Google Scholar 

  18. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080–1087.

    Article  PubMed  CAS  Google Scholar 

  19. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617–622.

    Article  PubMed  CAS  Google Scholar 

  20. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control Study. Am J Gastroenterol 2010.

  21. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.

    Article  PubMed  CAS  Google Scholar 

  22. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849–853.

    Article  PubMed  CAS  Google Scholar 

  23. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–2285.

    Article  PubMed  CAS  Google Scholar 

  24. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–630.

    Article  PubMed  CAS  Google Scholar 

  25. McDonald CJ, Overhage JM, Barnes M, et al. The Indiana network for patient care: a working local health information infrastructure. An example of a working infrastructure collaboration that links data from five health systems and hundreds of millions of entries. Health Aff (Millwood). 2005;24:1214–1220.

    Article  Google Scholar 

  26. McDonald CJ, Overhage JM, Tierney WM, et al. The Regenstrief Medical Record System: a quarter century experience. Int J Med Inform. 1999;54:225–253.

    Article  PubMed  CAS  Google Scholar 

  27. Overhage J, McDonald CJ, Suico JG. The Regenstrief medical record system 2000:Expanding the breadth and depth of a community wide EMR. Proc AMIA Symp 2000:1173.

  28. Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer. 1985;56:2914–2921.

    Article  PubMed  CAS  Google Scholar 

  29. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514–519.

    Article  PubMed  CAS  Google Scholar 

  30. Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95:2308–2312.

    Article  PubMed  Google Scholar 

  31. Feinstein AR, Walter SD, Horwitz RI. An analysis of Berkson’s bias in case-control studies. J Chronic Dis. 1986;39:495–504.

    Article  PubMed  CAS  Google Scholar 

  32. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–1125.

    Article  PubMed  CAS  Google Scholar 

  33. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–1625.

    Article  PubMed  CAS  Google Scholar 

  34. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024–1030.

    Article  PubMed  Google Scholar 

  35. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–653.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This paper was presented in part at the Digestive Disease Week, May 2007 in Washington, DC. We would like to thank Bridget Galetti for assistance with collecting the data.

Statement of interests

Dr. Michael Chiorean has received consulting/speaker fees from Centocor, Abbott, and UCB, who had no intellectual or financial input in this study. The other authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 550 N University Blvd., UH 4100, Indianapolis, IN, USA

    Michael V. Chiorean & Debra J. Helper

  2. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    Bhupesh Pokhrel & Jaya Adabala

  3. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA

    Cynthia S. Johnson & Beth Juliar

Authors
  1. Michael V. Chiorean
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhupesh Pokhrel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaya Adabala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Debra J. Helper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cynthia S. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Beth Juliar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael V. Chiorean.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiorean, M.V., Pokhrel, B., Adabala, J. et al. Incidence and Risk Factors for Lymphoma in a Single-Center Inflammatory Bowel Disease Population. Dig Dis Sci 56, 1489–1495 (2011). https://doi.org/10.1007/s10620-010-1430-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-010-1430-z

Keywords

Search

Navigation